Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical
company, today announced that it will release its first quarter ended
March 31, 2012 financial results on Thursday, May 10, 2012 before the
open of the U.S. financial markets. The Company will also conduct a
conference call that same morning at 8:30 a.m. ET (5:30 a.m. PT) to
discuss results and highlights of the first quarter of 2012.
The conference call will be available to interested parties through a
live audio Internet broadcast at http://investors.somaxon.com/events.cfm.
The call will also be archived and accessible at this site for
approximately two weeks. Alternatively, callers may participate in the
conference call by dialing (877) 941-9205 (domestic) or (480) 629-9866
(international), conference call ID 4534975. A telephonic replay will be
available for approximately two weeks following the conclusion of the
call by dialing (303) 590-3030, and entering passcode 4534975.
About Somaxon Pharmaceuticals, Inc.
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a
specialty pharmaceutical company focused on the in-licensing,
development and commercialization of proprietary branded products and
late-stage product candidates to treat important medical conditions
where there is an unmet medical need and/or high-level of patient
dissatisfaction, currently in the central nervous system therapeutic
area. Somaxon’s product Silenor, now available by prescription in the
United States, is indicated for the treatment of insomnia characterized
by difficulty with sleep maintenance.
For more information, please visit the company’s web site at www.somaxon.com.
